Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atigotatug +/- Nivolumab in Relapsed/Refractory SCLC
NCT02247349Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2014
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of Atigotatug in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Nov 2014; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02247349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02247349.